NCT05765994

Brief Summary

Small intestinal bacterial overgrowth (SIBO) syndrome, though associated with potentially serious complications, has not been adequately studied to date in critically ill patients hospitalized in intensive care units (ICU). A modified method for SIBO diagnosis is employed concerning a standard breath test. Specifically, as all participants are intubated and in need of mechanical ventilation, SIBO diagnosis is based on a non-invasive modified technique for sampling exhaled air from the ventilator tubes and performing a standard hydrogen breath test. The primary objective of this study is assessment of the prevalence of SIBO on ICU patients. Secondary outcomes include investigation of the effects of SIBO on ventilator associated pneumonia, as well as ICU length of stay and all-cause in-hospital mortality rate in critically ill patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 19, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 8, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2019

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

February 25, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 13, 2023

Completed
Last Updated

March 13, 2023

Status Verified

March 1, 2023

Enrollment Period

8 months

First QC Date

February 25, 2023

Last Update Submit

March 9, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • SIBO prevalence

    The proportion of ICU patients diagnosed with SIBO

    From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)

Secondary Outcomes (3)

  • VAP (ventilator associated pneumonia)

    From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)

  • ICU LOS

    From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)

  • All-cause in-hospital mortality

    From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)

Study Arms (1)

ICU patients

Adult ICU patients on mechanical ventilation

Diagnostic Test: Modified hydrogen breath test

Interventions

A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.

Also known as: Hydrogen monitor Gastrolyzer / Gastro+TM (Bedfont® Scientific Ltd,) was used for expired hydrogen (eH2) testing.
ICU patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult critically ill patients admitted to the ICU and in need of mechanical ventilation.

You may qualify if:

  • critically ill patients, in need of mechanical ventilation with an expected ICU length of stay and expected mechanical ventilation duration of more than 48 hours

You may not qualify if:

  • abnormal hydrogen breath test on the day of ICU admission (Day 1)
  • recent (up to four weeks before ICU admission) antimicrobial therapy or patients already receiving antimicrobial therapy on admission
  • recent (up to four weeks before ICU admission) use of gastroprotective medication, probiotics and prokinetics
  • patients with known gastrointestinal disease prior to admission
  • recent abdominal surgery resulting in planned or unplanned ICU admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Univesity Hospital of Ioannina

Ioannina, Epirus, 45500, Greece

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Anaesthesiology

Study Record Dates

First Submitted

February 25, 2023

First Posted

March 13, 2023

Study Start

November 19, 2018

Primary Completion

July 8, 2019

Study Completion

July 8, 2019

Last Updated

March 13, 2023

Record last verified: 2023-03

Locations